Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) were down 2.6% during mid-day trading on Monday . The stock traded as low as $21.14 and last traded at $21.37, with a volume of 106,897 shares. The stock had previously closed at $21.95.

Several analysts recently issued reports on ATRA shares. Jefferies Group reissued a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, April 9th. JMP Securities reissued a “buy” rating on shares of Atara Biotherapeutics in a research note on Saturday, July 9th. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research note on Tuesday, June 7th. Finally, Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 3rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $27.71.

The company has a 50 day moving average of $20.96 and a 200 day moving average of $19.05. The company’s market capitalization is $620.58 million.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.03. During the same period last year, the firm posted ($0.42) EPS. Equities research analysts anticipate that Atara Biotherapeutics Inc. will post ($2.64) EPS for the current fiscal year.

In other Atara Biotherapeutics news, insider Mitchall G. Clark sold 4,153 shares of the business’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $15.15, for a total value of $62,917.95. Following the sale, the insider now owns 87,912 shares in the company, valued at approximately $1,331,866.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Gad Soffer sold 5,427 shares of the business’s stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $15.91, for a total transaction of $86,343.57. Following the completion of the sale, the chief operating officer now owns 138,125 shares in the company, valued at approximately $2,197,568.75. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Atara Biotherapeutics stock. Jennison Associates increased its stake in Atara Biotherapeutics Inc. (NASDAQ:ATRA) by 40.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 844,180 shares of the company’s stock after buying an additional 244,695 shares during the period. Jennison Associates owned about 2.95% of Atara Biotherapeutics worth $26,541,000 at the end of the most recent quarter.

Atara Biotherapeutics, Inc is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for serious unmet medical needs with an initial focus on muscle wasting conditions and oncology. The Company’s lead product candidate, PINTA 745 is a peptibody that binds myostatin and inhibits its corresponding signal transduction, thereby blocking the negative regulation of skeletal muscle growth.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.